Blue Jet Healthcare, in their FY26 review, unveiled growth strategies for FY27, including a substantial investment of ₹1,000 Crore towards expansion. This move underscores the company's commitment to progress and development.

Despite Q4 results, Blue Jet Healthcare shares experienced an 8.3% surge. Analyst opinions are divided, with Emkay cautioning volatility and maintaining a 'Reduce' stance, while Motilal Oswal remains bullish due to growth potential in core segments, maintaining a 'Buy' recommendation.

Emkay has kept its recommendation for Blue Jet Healthcare at 'Reduce', lowering its price target to INR 450, signifying a potential decline of around 6.4%. Investors may wish to consider this negative outlook when making investment decisions regarding Blue Jet.

Blue Jet Healthcare has given the green light for an equity fundraise worth up to ₹1,000 crores. This move signals the company's intent to bolster its financial resources.

Motilal Oswal maintains a positive outlook on Blue Jet Healthcare, increasing their price target to ₹580 and recommending continued investment in the company.

Blue Jet Healthcare reported a 41.5% decrease in Q4 FY26 profit compared to the previous year due to a drop in revenue by 31.1%. Despite these setbacks, the company's stock managed to increase by 9.5%, reaching ₹482.5 - however, this is still 53.1% below its 52-week high.

Blue Jet Healthcare has given the green light to a fundraising plan worth up to 10 billion Indian rupees, aiming to fuel growth and expansion projects.

Blue Jet Healthcare's Q4 earnings report shows a significant drop in EBITDA by 49%, with the margin shrinking to 30.4%. This marks a decline compared to the previous year, indicating reduced profitability for the company during this period.

Blue Jet Healthcare has announced a dividend of ₹1.2 per share following the approval of its Q4 FY results and a clean audit opinion. The company also plans to raise ₹10,000 million through securities issuance, with an Extraordinary General Meeting (EGM) scheduled for June 17, 2026.

Blue Jet Healthcare reported a significant 42% decline in Q4 profits compared to last year, along with a 31% drop in overall revenue. These figures indicate challenging times for the healthcare company.

Blue Jet Healthcare will be announcing their Q4 results and discussing potential funding strategies at a board meeting scheduled for May 25, 2026. Investors eagerly await details of these financial results and any plans for additional funding.